Skip to main content
KALA BIO, Inc. logo

KALA BIO, Inc. — Investor Relations & Filings

Ticker · KALA ISIN · US4831192020 LEI · 529900Y7RO0C9P0TX474 US Manufacturing
Open in API
Filings indexed 644 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US KALA

About KALA BIO, Inc.

https://www.kalarx.com/

KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for rare and severe eye diseases. The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform to create therapies with regenerative healing effects. Its lead product candidate, KPI-012, is a topical therapy in a Phase 2b clinical study for the treatment of persistent corneal epithelial defect (PCED), for which it has received Orphan Drug and Fast Track designations from the U.S. FDA. The pipeline also includes KPI-014, a preclinical, gene-agnostic intravitreal therapy being developed for inherited retinal degenerations. Following the sale of its commercial products in 2022, KALA BIO has concentrated its efforts on advancing its biologics pipeline for ophthalmic conditions.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
10-K - KALA BIO, Inc. (0001479419) (Filer)
Annual Report FY 2025
2026-04-15 English
D - KALA BIO, Inc. (0001479419) (Filer)
Regulatory Filings
2026-03-17 English
144 - KALA BIO, Inc. (0001479419) (Subject)
Regulatory Filings
2026-03-17 English
8-K - KALA BIO, INC. (0001479419) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Platform Development and Exclusive License Agreement, and details about unregistered sales of equity securities related to that agreement. It also includes a press release attached as an exhibit. There are no financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or management report. The document is primarily an announcement of a significant business event and related securities issuance, which fits the category of Capital/Financing Update (CAP). The length and detail confirm it is the report itself, not just an announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2026-03-04 English
8-K - KALA BIO, INC. (0001479419) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The specific content of this filing is the resignation of a board member, David Lazar, from the Board of Directors of KALA BIO, Inc. This is clearly an announcement of a change in the company's board of directors. The document is short (3608 characters) and focuses solely on management change, with no financial data or other report content. Therefore, it fits the category of Board/Management Information (MANG).
2026-02-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.